295 related articles for article (PubMed ID: 17650522)
1. Systemic lupus erythematosus in a multiethnic US cohort LUMINA LI: anaemia as a predictor of disease activity and damage accrual.
Bertoli AM; Vilá LM; Apte M; Fessler BJ; Bastian HM; Reveille JD; Alarcón GS;
Rheumatology (Oxford); 2007 Sep; 46(9):1471-6. PubMed ID: 17650522
[TBL] [Abstract][Full Text] [Related]
2. Systemic lupus erythematosus in a multiethnic US cohort, XXXVII: association of lymphopenia with clinical manifestations, serologic abnormalities, disease activity, and damage accrual.
Vilá LM; Alarcón GS; McGwin G; Bastian HM; Fessler BJ; Reveille JD;
Arthritis Rheum; 2006 Oct; 55(5):799-806. PubMed ID: 17013840
[TBL] [Abstract][Full Text] [Related]
3. Early clinical manifestations, disease activity and damage of systemic lupus erythematosus among two distinct US Hispanic subpopulations.
Vilá LM; Alarcón GS; McGwin G; Friedman AW; Baethge BA; Bastian HM; Fessler BJ; Reveille JD;
Rheumatology (Oxford); 2004 Mar; 43(3):358-63. PubMed ID: 14623949
[TBL] [Abstract][Full Text] [Related]
4. Systemic lupus erythematosus in a multiethnic US cohort (LUMINA): XXI. Disease activity, damage accrual, and vascular events in pre- and postmenopausal women.
Fernández M; Calvo-Alén J; Alarcón GS; Roseman JM; Bastian HM; Fessler BJ; McGwin G; Vilá LM; Sanchez ML; Reveille JD
Arthritis Rheum; 2005 Jun; 52(6):1655-64. PubMed ID: 15934092
[TBL] [Abstract][Full Text] [Related]
5. Predictors of neuropsychiatric damage in systemic lupus erythematosus: data from the Maryland lupus cohort.
Mikdashi J; Handwerger B
Rheumatology (Oxford); 2004 Dec; 43(12):1555-60. PubMed ID: 15342927
[TBL] [Abstract][Full Text] [Related]
6. Damage accumulation in systemic lupus erythematosus and its relation to disease activity and mortality.
Becker-Merok A; Nossent HC
J Rheumatol; 2006 Aug; 33(8):1570-7. PubMed ID: 16845708
[TBL] [Abstract][Full Text] [Related]
7. The impact of increased body mass index on systemic lupus erythematosus: data from LUMINA, a multiethnic cohort (LUMINA XLVI) [corrected].
Chaiamnuay S; Bertoli AM; Fernández M; Apte M; Vilá LM; Reveille JD; Alarcón GS;
J Clin Rheumatol; 2007 Jun; 13(3):128-33. PubMed ID: 17551377
[TBL] [Abstract][Full Text] [Related]
8. Systemic lupus erythematosus in a multiethnic cohort (LUMINA): XXIX. Elevation of erythrocyte sedimentation rate is associated with disease activity and damage accrual.
Vilá LM; Alarcón GS; McGwin G; Bastian HM; Fessler BJ; Reveille JD;
J Rheumatol; 2005 Nov; 32(11):2150-5. PubMed ID: 16265693
[TBL] [Abstract][Full Text] [Related]
9. Lymphopenia is associated with neuropsychiatric manifestations and disease activity in paediatric systemic lupus erythematosus patients.
Yu HH; Wang LC; Lee JH; Lee CC; Yang YH; Chiang BL
Rheumatology (Oxford); 2007 Sep; 46(9):1492-4. PubMed ID: 17673480
[TBL] [Abstract][Full Text] [Related]
10. Effect of disease activity and damage on quality of life in patients with systemic lupus erythematosus: a 2-year prospective study.
Mok CC; Ho LY; Cheung MY; Yu KL; To CH
Scand J Rheumatol; 2009; 38(2):121-7. PubMed ID: 18991189
[TBL] [Abstract][Full Text] [Related]
11. Activation of the interferon-alpha pathway identifies a subgroup of systemic lupus erythematosus patients with distinct serologic features and active disease.
Kirou KA; Lee C; George S; Louca K; Peterson MG; Crow MK
Arthritis Rheum; 2005 May; 52(5):1491-503. PubMed ID: 15880830
[TBL] [Abstract][Full Text] [Related]
12. Anti-nucleosome antibodies in patients with systemic lupus erythematosus of recent onset. Potential utility as a diagnostic tool and disease activity marker.
Simón JA; Cabiedes J; Ortiz E; Alcocer-Varela J; Sánchez-Guerrero J
Rheumatology (Oxford); 2004 Feb; 43(2):220-4. PubMed ID: 13130152
[TBL] [Abstract][Full Text] [Related]
13. Analysis of the relationship between disease activity and damage in patients with systemic lupus erythematosus--a 5-yr prospective study.
Stoll T; Sutcliffe N; Mach J; Klaghofer R; Isenberg DA
Rheumatology (Oxford); 2004 Aug; 43(8):1039-44. PubMed ID: 15161983
[TBL] [Abstract][Full Text] [Related]
14. Initial and accrued damage as predictors of mortality in Brazilian patients with systemic lupus erythematosus: a cohort study.
Cardoso CR; Signorelli FV; Papi JA; Salles GF
Lupus; 2008 Nov; 17(11):1042-8. PubMed ID: 18852231
[TBL] [Abstract][Full Text] [Related]
15. The effect of menopause on disease activity in systemic lupus erythematosus.
Urowitz MB; Ibañez D; Jerome D; Gladman DD
J Rheumatol; 2006 Nov; 33(11):2192-8. PubMed ID: 16981295
[TBL] [Abstract][Full Text] [Related]
16. Learning from discordance in patient and physician global assessments of systemic lupus erythematosus disease activity.
Neville C; Clarke AE; Joseph L; Belisle P; Ferland D; Fortin PR
J Rheumatol; 2000 Mar; 27(3):675-9. PubMed ID: 10743807
[TBL] [Abstract][Full Text] [Related]
17. Anti-nucleosome and anti-chromatin antibodies are present in active systemic lupus erythematosus but not in the cutaneous form of the disease.
Souza A; da Silva LM; Oliveira FR; Roselino AM; Louzada-Junior P
Lupus; 2009 Mar; 18(3):223-9. PubMed ID: 19213860
[TBL] [Abstract][Full Text] [Related]
18. Clinical and serologic factors associated with lupus pleuritis.
Mittoo S; Gelber AC; Hitchon CA; Silverman ED; Pope JE; Fortin PR; Pineau C; Smith CD; Arbillaga H; Gladman DD; Urowitz MB; Zummer M; Clarke AE; Bernatsky S; Hudson M; Tucker LB; Petty RE; ; Peschken CA
J Rheumatol; 2010 Apr; 37(4):747-53. PubMed ID: 20110526
[TBL] [Abstract][Full Text] [Related]
19. VH4-34 encoded antibodies in systemic lupus erythematosus: a specific diagnostic marker that correlates with clinical disease characteristics.
van Vollenhoven RF; Bieber MM; Powell MJ; Gupta PK; Bhat NM; Richards KL; Albano SA; Teng NN
J Rheumatol; 1999 Aug; 26(8):1727-33. PubMed ID: 10451069
[TBL] [Abstract][Full Text] [Related]
20. Is antibody clustering predictive of clinical subsets and damage in systemic lupus erythematosus?
To CH; Petri M
Arthritis Rheum; 2005 Dec; 52(12):4003-10. PubMed ID: 16320348
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
